PubMed:26646445 / 1338-1501 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T9","span":{"begin":0,"end":163},"obj":"Sentence"},{"id":"T9","span":{"begin":0,"end":163},"obj":"Sentence"},{"id":"T9","span":{"begin":0,"end":163},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"GlycoBiology-FMA","denotations":[{"id":"_T19","span":{"begin":71,"end":77},"obj":"FMAID:97486"},{"id":"_T20","span":{"begin":71,"end":77},"obj":"FMAID:9601"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"uniprot-human","denotations":[{"id":"T5","span":{"begin":140,"end":143},"obj":"http://www.uniprot.org/uniprot/P06731"},{"id":"T7","span":{"begin":145,"end":152},"obj":"http://www.uniprot.org/uniprot/Q9BXA4"},{"id":"T9","span":{"begin":157,"end":162},"obj":"http://www.uniprot.org/uniprot/Q8WXI7"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T12","span":{"begin":78,"end":84},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/6754"},{"id":"T13","span":{"begin":140,"end":143},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/1107390"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"GO-BP","denotations":[{"id":"T8","span":{"begin":140,"end":143},"obj":"http://purl.obolibrary.org/obo/GO_0033848"},{"id":"T10","span":{"begin":145,"end":147},"obj":"http://purl.obolibrary.org/obo/GO_0033968"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"UBERON-AE","denotations":[{"id":"T7","span":{"begin":71,"end":77},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"GlycoBiology-Motifs","denotations":[{"id":"T5","span":{"begin":43,"end":51},"obj":"http://rdf.glycoinfo.org/glycan/G00027MO"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"Lectin","denotations":[{"id":"Lectin_T1","span":{"begin":145,"end":147},"obj":"https://acgg.asia/db/lfdb/LfDB0227"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T6","span":{"begin":71,"end":77},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"mondo_disease","denotations":[{"id":"T7","span":{"begin":71,"end":84},"obj":"Disease"}],"attributes":[{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"HP-phenotype","denotations":[{"id":"T8","span":{"begin":71,"end":84},"obj":"Phenotype"}],"attributes":[{"id":"A8","pred":"hp_id","subj":"T8","obj":"HP:0003002"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"GlyCosmos15-HP","denotations":[{"id":"T8","span":{"begin":71,"end":84},"obj":"Phenotype"}],"attributes":[{"id":"A8","pred":"hp_id","subj":"T8","obj":"HP:0003002"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"GlyCosmos15-MONDO","denotations":[{"id":"T7","span":{"begin":71,"end":84},"obj":"Disease"}],"attributes":[{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0007254"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"GlyCosmos15-UBERON","denotations":[{"id":"T6","span":{"begin":71,"end":77},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T9","span":{"begin":0,"end":163},"obj":"Sentence"},{"id":"T9","span":{"begin":0,"end":163},"obj":"Sentence"},{"id":"T9","span":{"begin":0,"end":163},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T9","span":{"begin":0,"end":163},"obj":"Sentence"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}

{"project":"Anatomy-UBERON","denotations":[{"id":"T6","span":{"begin":71,"end":77},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125."}